Pseudohypoparathyroidism showing positive phosphaturic and negative cyclic AMP excretion response to parathyroid hormone.
We report a patient with pseudohypoparathyroidism (PHP) in whom parathyroid hormone (PTH) infusion failed to produce an increase in urinary adenosine 3', 5' monophosphate (cAMP) excretion in spite of the positive urinary phosphate excretion. The dbcAMP infusion test showed almost the same increase in phosphate as in the E-H test, although high urinary cAMP excretion was detected. Furthermore, a PTH infusion test in combination with calcium antagonist (diltiazem) administration markedly increased phosphate excretion, whereas the response of urinary cAMP excretion also remained negative. After treatment with 1 alpha(OH)D3, phosphaturic response increased by at least 14.3 mg/2 h compared with that in the pretreatment period. Therefore, intra and extra cellular calcium seem to affect the phosphaturic response induced by PTH.
Higashi
K
K
Department of Internal Medicine, Kumamoto National Hospital, Japan.
Honda
K
K
Morita
M
M
Umeda
T
T
Shimada
T
T
Kimura
K
K
Shido
T
T
Arita
I
I
Sato
T
T
D000328:Adult; D003404:Creatinine / Q000652:urine; D000242:Cyclic AMP / Q000652:urine*; D004110:Diltiazem; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D010281:Parathyroid Hormone; D010710:Phosphates / Q000652:urine*; D011547:Pseudohypoparathyroidism / Q000188:drug therapy / Q000652:urine*
D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D010710:Phosphates; D003404:Creatinine; D000242:Cyclic AMP; D004110:Diltiazem; C008088:alfacalcidol